Karl Deisseroth
Biotech

How Nobel-winning optogenetics is being harnessed by biotechs

Fierce spoke to Nobel Prize winner Karl Deisseroth, M.D., Ph.D., and other optogenetics pioneers to discover how this science could benefit patients.
Darren Incorvaia Oct 9, 2026 9:30am
Stock market IPO share price

Parkinson’s-focused Aspen and bispecific biotech Aspen plan IPOs

Oct 10, 2026 11:08am
GSK

GSK drinks in Chai’s AI models after wet-lab validation

Oct 9, 2026 10:36am
Illustration for Fierces Chutes Ladders feature showing a blue city skyline with executives making career moves o

Vir looks to Liu to lead late-stage push—Chutes & Ladders

Oct 9, 2026 8:30am
Podcast
Fierce 15

How we picked the Fierce 15

Oct 9, 2026 7:21am
T-Rex dinosaur

TRex rakes in $117M IPO, while Retension reveals $45M listing

Oct 9, 2026 4:29am
More News

Endeavor Hedgehog inhibitor has potential to shake up IPF space

Oct 8, 2026 9:50am

Iambic aims for $135M IPO to push cancer drugs through clinic

Oct 8, 2026 8:45am

‘It’s just survival’: Why a third of Boston lab space sits empty

Oct 8, 2026 8:00am

Ono pays $80M for local rights to trio of Biohaven IgG degraders

Oct 8, 2026 5:23am